12,372 trials
Acute Schizophrenia
Primary: PANSS Total Score Mean Change From Baseline to Endpoint — -24.6; -24.7; -11.0 units on a scale
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population — 5.1; 42.2…
Ovarian Cancer
Primary: Efficacy Patient Level — 26.9 percentage of participants
COVID-19 · SARS-CoV2
Primary: Percentage of Participants With COVID-19 — 15.7; 8.3 Percentage of Participants — p=<0.001
Hemophilia A · Hemophilia B
Primary: Estimated Annualized Bleeding Rate (ABR) for Treated Bleeds During the Efficacy Period — 30.991; 3.133 episodes per participant per year — p=<0.0001
Metabolism and Nutrition Disorder · Obesity
Primary: Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks — -0.18; -0.18; -0.50; -0.48 SDS score
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
Atopic Dermatitis
Primary: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 — 16.3; 69.6; 79.7…
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 4.8; 85.0; 49.7 percentage of participants — p=<0.001
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) Occurring in ≥5% of Participants in Any Treatment Group — 306; 353; 135; 140 participants
Older Adults · Physical Function · Cognitive Function
Primary: Curcumin and Physical Function -Walking — 0.014; 0.103 meters/second
Acute Lymphoblastic Leukemia, in Relapse
Primary: Duration of Asparaginase Activity >100 U/L During Induction — 18.9; 8.5 days
Atopic Dermatitis
Primary: Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16 — 62.6; 72.4 percentage of participants…
Rheumatoid Arthritis
Primary: Number of Participants Who Experienced Adverse Events (AEs) or Serious AE — 234; 1532; 270; 315 participants
Acute Repetitive Seizures · Breakthrough Seizures
Primary: Number of Participants Who Received NRL-1 (Valtoco) — 9; 54; 46; 54 Participants